Just 2,000 patients have been treated so far with Leqembi, Biogen said Tuesday, a warning that the Alzheimer's drug developed with Eisai Co. may miss its target of 10,000 recipients by the end of March.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
